155 related articles for article (PubMed ID: 26700812)
1. Cancer: Oncogene brought into the loop.
Grimmer MR; Costello JF
Nature; 2016 Jan; 529(7584):34-5. PubMed ID: 26700812
[TBL] [Abstract][Full Text] [Related]
2. CNS cancer: Breaking boundaries - IDH mutations in glioma.
Killock D
Nat Rev Clin Oncol; 2016 Feb; 13(2):64. PubMed ID: 26787277
[No Abstract] [Full Text] [Related]
3. Oncometabolite Tinkers with Genome Folding, Boosting Oncogene Expression.
Ing-Simmons E; Merkenschlager M
Trends Mol Med; 2016 Mar; 22(3):185-187. PubMed ID: 26856236
[TBL] [Abstract][Full Text] [Related]
4. Bringing IDH into the Fold.
Zadeh G; Aldape K
Cancer Cell; 2016 Feb; 29(2):139-40. PubMed ID: 26859452
[TBL] [Abstract][Full Text] [Related]
5. Insulator dysfunction and oncogene activation in IDH mutant gliomas.
Flavahan WA; Drier Y; Liau BB; Gillespie SM; Venteicher AS; Stemmer-Rachamimov AO; Suvà ML; Bernstein BE
Nature; 2016 Jan; 529(7584):110-4. PubMed ID: 26700815
[TBL] [Abstract][Full Text] [Related]
6. From standard treatment to personalized medicine: role of IDH1 mutations in low-grade glioma evolution and treatment.
Ferroli P; Acerbi F; Finocchiaro G
World Neurosurg; 2010 Apr; 73(4):234-6. PubMed ID: 20849763
[No Abstract] [Full Text] [Related]
7. IDH1 and IDH2 mutations in gliomas and the associated induction of hypoxia-inducible factor and production of 2-hydroxyglutarate.
Komotar RJ; Starke RM; Sisti MB; Connolly ES
Neurosurgery; 2010 Apr; 66(4):N20-1. PubMed ID: 20305482
[No Abstract] [Full Text] [Related]
8. Isocitrate dehydrogenase 1 mutation subtypes at site 132 and their translational potential in glioma.
Lu VM; McDonald KL
CNS Oncol; 2018 Jan; 7(1):41-50. PubMed ID: 29303363
[TBL] [Abstract][Full Text] [Related]
9. Oncogenic MicroRNA-20a is downregulated by the HIF-1α/c-MYC pathway in IDH1 R132H-mutant glioma.
Xu Q; Ahmed AK; Zhu Y; Wang K; Lv S; Li Y; Jiang Y
Biochem Biophys Res Commun; 2018 May; 499(4):882-888. PubMed ID: 29625108
[TBL] [Abstract][Full Text] [Related]
10. Identification of a three-long non-coding RNA signature for predicting survival of temozolomide-treated isocitrate dehydrogenase mutant low-grade gliomas.
Li R; Chen W; Mao P; Wang J; Jing J; Sun Q; Wang M; Yu X
Exp Biol Med (Maywood); 2021 Jan; 246(2):187-196. PubMed ID: 33028081
[TBL] [Abstract][Full Text] [Related]
11. Isocitrate dehydrogenase 1: what it means to the neurosurgeon: a review.
Hodges TR; Choi BD; Bigner DD; Yan H; Sampson JH
J Neurosurg; 2013 Jun; 118(6):1176-80. PubMed ID: 23581583
[TBL] [Abstract][Full Text] [Related]
12. PD-1 (PDCD1) Promoter Methylation Is a Prognostic Factor in Patients With Diffuse Lower-Grade Gliomas Harboring Isocitrate Dehydrogenase (IDH) Mutations.
Röver LK; Gevensleben H; Dietrich J; Bootz F; Landsberg J; Goltz D; Dietrich D
EBioMedicine; 2018 Feb; 28():97-104. PubMed ID: 29396294
[TBL] [Abstract][Full Text] [Related]
13. Oncogenic KRAS hotspot mutations are rare in IDH-mutant gliomas.
Schittenhelm J; Krischker N; Gepfner-Tuma I; Behling F; Noell S; Eckert F; Biskup S; Tabatabai G
Brain Pathol; 2019 May; 29(3):321-324. PubMed ID: 30676672
[No Abstract] [Full Text] [Related]
14. IDH mutation status in prostate cancer.
Ghiam AF; Cairns RA; Thoms J; Dal Pra A; Ahmed O; Meng A; Mak TW; Bristow RG
Oncogene; 2012 Aug; 31(33):3826. PubMed ID: 22120718
[No Abstract] [Full Text] [Related]
15. IDH1 gene mutations: a new paradigm in glioma prognosis and therapy?
Labussiere M; Sanson M; Idbaih A; Delattre JY
Oncologist; 2010; 15(2):196-9. PubMed ID: 20133500
[TBL] [Abstract][Full Text] [Related]
16. To be Wild or Mutant: Role of Isocitrate Dehydrogenase 1 (IDH1) and 2-Hydroxy Glutarate (2-HG) in Gliomagenesis and Treatment Outcome in Glioma.
Bhavya B; Anand CR; Madhusoodanan UK; Rajalakshmi P; Krishnakumar K; Easwer HV; Deepti AN; Gopala S
Cell Mol Neurobiol; 2020 Jan; 40(1):53-63. PubMed ID: 31485826
[TBL] [Abstract][Full Text] [Related]
17. R132 mutations in canine isocitrate dehydrogenase 1 (IDH1) lead to functional changes.
Kawakami S; Ochiai K; Azakami D; Kato Y; Michishita M; Morimatsu M; Ishiguro-Oonuma T; Onozawa E; Watanabe M; Omi T
Vet Res Commun; 2018 Mar; 42(1):49-56. PubMed ID: 29285579
[TBL] [Abstract][Full Text] [Related]
18. Isocitrate dehydrogenase mutations in gliomas.
Waitkus MS; Diplas BH; Yan H
Neuro Oncol; 2016 Jan; 18(1):16-26. PubMed ID: 26188014
[TBL] [Abstract][Full Text] [Related]
19. Cancer-associated IDH mutations: biomarker and therapeutic opportunities.
Yen KE; Bittinger MA; Su SM; Fantin VR
Oncogene; 2010 Dec; 29(49):6409-17. PubMed ID: 20972461
[TBL] [Abstract][Full Text] [Related]
20. Metabolism: reprogramming metabolic flux in glioma.
Lokody I
Nat Rev Cancer; 2014 Nov; 14(11):706-7. PubMed ID: 25291294
[No Abstract] [Full Text] [Related]
[Next] [New Search]
